The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
